Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disorder associated with features of metabolic syndrome and oxidative stress. We examined the mechanism by which the combined extracts of
Rhus verniciflua
and
Eucommia ulmoides
extracts (
ILF
-RE) regulate hepatic dyslipidemia in an established NAFLD model, high-fat diet (HFD)-induced lipid dysmetabolism in rats.
ILF
-RE attenuated alanine aminotransferase (ALT) by 1.5%
(
p
<
0
.
0
5
)
, aspartate aminotransferase (AST) by 1.5%
(
p
<
0
.
0
5
)
, triglycerides by 1.5%
(
p
<
0
.
0
5
)
, cholesterol by 2.0%
(
p
<
0
.
0
5
)
, and lipid peroxidation by 1.5%
(
p
<
0
.
0
5
)
in the NAFLD model.
ILF
-RE, recently shown to have anti-oxidant properties, also inhibited hepatic ROS accumulation by 1.68%
(
p
<
0
.
0
5
)
and regulated ER-redox imbalance, a key phenomenon of ER stress. Due to nutrient overload stress-associated protein folding, ER stress and downstream SREBP-lipogenic transcription signaling were highly activated, and the mTORC1-AMPK axis was also disturbed, leading to
hepatic steatosis
.
ILF
-RE results in recovery from hepatic conditions induced by nutrient-based protein folding stress signaling and the ER stress-SREBP and AMPK-mTORC1-SREBP1 axes. Based on these results,
ILF
-RE is suggested to be a potential therapeutic strategy for
hepatic steatosis
and may represent a promising novel agent for the prevention and treatment of NAFLD.
...
PMID:
Rhus verniciflua
and
Eucommia ulmoides
Protects Against High-Fat Diet-Induced Hepatic Steatosis by Enhancing Anti-Oxidation and AMPK Activation. 3148 34
